Our COO & co-founder, Ivan Mishanin, has published an insightful article on ScienceTimes.com, exploring the challenges and opportunities in depression treatment development. Mishanin discusses rising costs, low approval rates, patent expirations, and the impact of these factors on the pharmaceutical industry. He emphasizes the importance of embracing alternative solutions, collaborative efforts, and emerging technologies to reshape mental health care's future. This comprehensive analysis is a must-read for entrepreneurs and business leaders looking to invest in the rapidly evolving field of depression treatment development.